查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1397048

肿瘤消融市场：按技术、治疗和应用分类：2022-2032 年全球机会分析和产业预测

Tumor Ablation Market By Technology, By Treatment, By Application : Global Opportunity Analysis and Industry Forecast, 2022-2032
出版日期: | 出版商: Allied Market Research | 英文 240 Pages | 商品交期: 2-3个工作天内

价格

2022年肿瘤消融市值为14.1385亿美元，预计2032年将达到50.3244亿美元，2022年至2032年的复合年增长率为13.5%。

肿瘤消融技术，也称为微创技术，用于治疗肾臟、骨骼、肝臟和肺部的肿瘤。它利用热量来瞄准特定的癌细胞。这种针状装置含有一种发热成分，可以杀死目标癌细胞。它是在体内进行的，无需将肿瘤从体内切除。

这种方法透过插入探针并在精确的电脑断层扫描下将其加热至摄氏 100 度来去除良性肿瘤。有多种肿瘤消融方法可用于诊断和治疗疾病，包括微波消融、射频消融和冷冻。重复使用消融技术可以减轻患者的疼痛和风险，提高精确度，并治疗更广泛的癌症类型。

全球肿瘤消融市场的成长主要是由于癌症盛行率的不断上升以及肿瘤消融治疗的高采用率所推动的。此外，技术先进的肿瘤消融技术的采用和出现，例如热感消融、雷射消熔、不可逆电穿孔以及高强度聚焦超音波（HIFU）的出现，都是影响市场成长的因素。提高消融技术使用的安全性、增加老年人口以及增加公私倡议和资金以支持与肿瘤消融相关的持续研究活动正在推动市场成长。

癌症是一种毁灭性且可能危及生命的疾病，在世界各地的发病率正在稳步上升。例如，根据国家卫生统计中心的数据。这种激增是由于多种因素造成的，包括高龄化、生活方式的改变以及能够更早发现肿瘤的诊断技术的改进。肿瘤消融技术在肿瘤学领域引起了广泛关注，因为它们无需进行大量手术即可破坏癌组织。

此外，肿瘤消融技术通常用于不适合手术的患者或作为缓解晚期癌症症状的安宁疗护。癌症盛行率的增加不仅增加了对肿瘤消融手术的需求，而且刺激了持续的研究和开发工作，以提高这些治疗方法的有效性和可及性。由此，肿瘤消融市场的技术创新加速，先进技术和设备的引进，进一步推动了市场成长。因此，癌症盛行率的增加预计将推动市场成长。

此外，基于肿瘤消融的治疗方法的高采用率已成为肿瘤消融市场成长的关键驱动力。近年来，射频消融（RFA）、微波消融、冷冻等肿瘤消融技术因其对肝肿瘤、肺肿瘤、肾肿瘤、骨肿瘤等多种肿瘤的有效治疗而受到广泛欢迎。 。与传统手术方法相比，肿瘤消融技术有几个明显的优势。它是微创的，这意味着切口很小，或者在某些情况下根本没有切口。这可以缩短復健时间、缩短住院时间并减少术后併发症，使其成为对患者和医疗保健提供者都有吸引力的选择。

例如，美国国家医学图书馆 2021 年的一份报告发现，对于孤立性肝细胞癌，经皮消融是安全的，几乎与手术一样有效，通常成本更低，住院时间更短。据报道，这已经足够了。此外，技术和影像的进步显着提高了肿瘤消融手术的精确度和准确性。超音波、 电脑断层扫描和MRI等即时影像引导使医疗专业人员能够在切除过程中精确瞄准和监测肿瘤，在切除癌组织的同时不伤害周围健康的器官和组织，从而可以彻底破坏肿瘤。因此，基于肿瘤消融的治疗方法的采用预计将激增，从而对市场成长做出重大贡献。

然而，与肿瘤消融治疗相关的副作用可能会抑制市场成长。此外，肿瘤消融领域研发活动的活性化预计将为市场提供重大成长机会。肿瘤消融市场按技术、治疗、应用和地区细分。依技术分为射频消融术、微波消融、冷冻、不可逆电穿孔消融等。治疗方法分为手术消融、腹腔镜消融、经皮消融。依用途分为肾癌、肝癌、乳癌、肺癌、摄护腺癌和骨癌。依区域划分，在北美（美国、加拿大、墨西哥）、欧洲（美国、加拿大、墨西哥）、北美（美国、加拿大、墨西哥）、欧洲（德国、法国、英国、义大利、西班牙、亚洲其他地区）进行分析-太平洋）。亚太地区（日本、中国、澳洲、印度、韩国、亚太地区其他地区）和LAMEA（巴西、南非、沙乌地阿拉伯、其他欧洲国家）。全球肿瘤消融市场的主要企业有美敦力公司、波士顿科学公司、史密斯和乐辉公司、Integra LifeSciences Holding Corporation、AngioDynamics Inc、HealthTronics, Inc、Bioventus (Misonix Inc)、强生公司、ConMed Corporation、奥林巴斯公司。

目录

第一章简介

第 2 章执行摘要

第三章市场概况

  • 市场定义和范围
  • 主要发现
    • 影响因素
    • 主要投资机会
  • 波特五力分析
  • 市场动态
    • 促进因素
      • 全球癌症盛行率不断上升。
      • 对微创肿瘤消融技术的需求不断增加
    • 抑制因素
      • 与肿瘤消融治疗相关的副作用
    • 机会
      • 活性化肿瘤消融的研发活动

第四章肿瘤消融市场：依技术分类

  • 概述
  • 射频消融术
  • 微波消融
  • 冷冻
  • 不可逆电穿孔消融
  • 其他消融技术

第五章肿瘤消融市场：依治疗方式

  • 概述
  • 手术消融
  • 腹腔镜消融术
  • 经皮术

第六章肿瘤消融市场：依应用分类

  • 概述
  • 肾癌
  • 肝癌
  • 乳癌
  • 肺癌
  • 摄护腺癌
  • 骨癌

第七章肿瘤消融市场：按地区

  • 概述
  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 法国
    • 英国
    • 义大利
    • 西班牙
    • 其他的
  • 亚太地区
    • 日本
    • 中国
    • 澳洲
    • 印度
    • 韩国
    • 其他的
  • 拉丁美洲/中东/非洲
    • 巴西
    • 沙乌地阿拉伯
    • 南非
    • 其他的

第八章 竞争形势

  • 介绍
  • 关键成功策略
  • 10家主要企业产品图谱
  • 竞争仪表板
  • 竞争热图
  • 2022年主要企业定位

第九章 公司简介

  • Medtronic plc
  • Boston Scientific Corporation
  • Smith & Nephew plc
  • AngioDynamics, Inc.
  • HealthTronics, Inc.
  • Bioventus LLC
  • Johnson & Johnson
  • ConMed Corporation
  • Olympus Corporation
  • Integra LifeSciences Holdings Corporation
Product Code: A17208

The tumor ablation market was valued at $1,413.85 million in 2022 and is estimated to reach $5,032.44 million by 2032, exhibiting a CAGR of 13.5% from 2022 to 2032. Tumor ablation techniques, also referred to as minimally invasive technology, are used to treat tumors of kidney, bones, liver, and lungs. They use heat to target a specific tumor cell. It is a needle-like device with a heat-generating component that leads to cellular necrosis of targeted tumor cell. It is performed in-vivo, without taking tumors out of the body.

The method eliminates benign tumors by inserting a probe and heating it to 100 degrees Celsius under precise computer tomography. There are different methods available for tumor ablation such as microwave ablation, radiofrequency ablation, cryoablation, and others that can be used for disease diagnosis and treatment. Repeated use of ablation methods helps reduce patient's pain and risk while increasing accuracy and treating a broader type of cancer.

The growth of the global tumor ablation market is majorly driven by increase in prevalence of cancer, and high adoption of the tumor ablation-based treatments. Moreover, adoption and emergence of technologically advanced tumor ablation techniques including the advent of thermal and laser ablation, irreversible electroporation, and high-intensity focused ultrasound (HIFU) are the factors that influence the market growth. Increase in safety regarding use of ablation techniques, increase in geriatric population, and increase in public-private initiatives & funding to support ongoing research activities related to tumor ablation drive the market growth.

Cancer, a devastating and potentially life-threatening disease, has been steadily increasing in incidence across the globe. For instance, according to the National Center for Health Statistics. In 2023, 1,958,310 new cancer cases and 609,820 cancer deaths are projected to occur in the U.S. This surge can be attributed to several factors, including an aging population, lifestyle changes, and improved diagnostics that enable earlier detection of tumors. Tumor ablation techniques have gained significant prominence in the field of oncology due to their ability to destroy cancerous tissue without the need for extensive surgeries.

Additionally, tumor ablation techniques are often utilized for patients who are not candidates for surgery or as a palliative option to relieve symptoms in advanced cancer cases. The increasing prevalence of cancer not only drives the demand for tumor ablation procedures but also stimulates ongoing research and development efforts to enhance the efficacy and accessibility of these treatments. This, in turn, fosters innovation in the tumor ablation market, leading to the introduction of advanced technologies and improved devices, which further boosts market growth. Thus, the rise in prevalence of cancer is expected to drive the growth of the market.

Furthermore, the high adoption of tumor ablation-based treatments has emerged as a major driving factor for the growth of the tumor ablation market. Tumor ablation techniques, such as radiofrequency ablation (RFA), microwave ablation, and cryoablation, have gained significant popularity in recent years due to their effectiveness in treating various types of tumors, including liver, lung, kidney, and bone tumors. Tumor ablation procedures offer several distinct advantages over traditional surgical methods. They are minimally invasive, which means they involve smaller incisions or, in some cases, no incisions at all. This results in shorter recovery times, reduced hospital stays, and lower post-operative complications, making them more attractive options for both patients and healthcare providers.

For instance, according to a 2021 report by the National Library of Medicine, it was reported that percutaneous ablation is safe and nearly as efficacious as surgery, usually requiring a lower cost and shorter hospital stay for single hepatocellular carcinoma. In addition, advancements in technology and imaging have greatly improved the precision and accuracy of tumor ablation procedures. Real-time imaging guidance, such as ultrasound, CT scans, or MRI, allows medical professionals to precisely target and monitor the tumor during the ablation process, ensuring thorough destruction of the cancerous tissue while sparing healthy surrounding organs and tissues. Thus, the surge in adoption of tumor ablation-based treatments is expected to significantly contribute to the growth of the market.

However, side-effects associated with tumor ablation treatment might restrain the growth of the market. Moreover, a rise in research and development activities for tumor ablation is expected to present significant growth opportunities to the market. The tumor ablation market is segmented on the basis of technology, treatment, application, and region. By technology, the market is classified into radiofrequency ablation, microwave ablation, cryo-ablation, irreversible electroporation ablation, and others. By treatment, it is classified into surgical ablation, laparoscopic ablation, and percutaneous ablation. By application, it is classified into kidney cancer, liver cancer, breast cancer, lung cancer, prostate cancer and bone cancer. Region-wise, the market is analyzed across North America (the U.S., Canada, and Mexico), Europe (Germany, France, the UK, Italy, Spain, and rest of Europe), Asia-Pacific (Japan, China, Australia, India, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, South Africa, Saudi Arabia, and rest of LAMEA).Major key players that operate in the global tumor ablation market are Medtronic plc, Boston Scientific Corporation, Smith and Nephew PLC, Integra LifeSciences Holding Corporation, AngioDynamics Inc, HealthTronics, Inc, Bioventus (Misonix Inc), Johnson and Johnson, ConMed Corporation and Olympus Corporation.

Key Benefits For Stakeholders

  • This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the tumor ablation market analysis from 2022 to 2032 to identify the prevailing tumor ablation market opportunities.
  • The market research is offered along with information related to key drivers, restraints, and opportunities.
  • Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
  • In-depth analysis of the tumor ablation market segmentation assists to determine the prevailing market opportunities.
  • Major countries in each region are mapped according to their revenue contribution to the global market.
  • Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
  • The report includes the analysis of the regional as well as global tumor ablation market trends, key players, market segments, application areas, and market growth strategies.

Additional benefits you will get with this purchase are:

  • Quarterly Update and* (only available with a corporate license, on listed price)
  • 5 additional Company Profile of client Choice pre- or Post-purchase, as a free update.
  • Free Upcoming Version on the Purchase of Five and Enterprise User License.
  • 16 analyst hours of support* (post-purchase, if you find additional data requirements upon review of the report, you may receive support amounting to 16 analyst hours to solve questions, and post-sale queries)
  • 15% Free Customization* (in case the scope or segment of the report does not match your requirements, 15% is equivalent to 3 working days of free work, applicable once)
  • Free data Pack on the Five and Enterprise User License. (Excel version of the report)
  • Free Updated report if the report is 6-12 months old or older.
  • 24-hour priority response*
  • Free Industry updates and white papers.

Possible Customization with this report (with additional cost and timeline, please talk to the sales executive to know more)

  • Market share analysis of players by products/segments
  • New Product Development/ Product Matrix of Key Players
  • Additional company profiles with specific to client's interest
  • Additional country or region analysis- market size and forecast
  • Average Selling Price Analysis / Price Point Analysis
  • Expanded list for Company Profiles
  • Historic market data
  • SWOT Analysis

Key Market Segments

By Technology

  • Radiofrequency Ablation
  • Microwave Ablation
  • Cryoablation
  • Irreversible Electroporation Ablation
  • Other Ablation Technologies

By Treatment

  • Surgical Ablation
  • Laparoscopic Ablation
  • Percutaneous Ablation

By Application

  • Kidney Cancer
  • Liver Cancer
  • Breast Cancer
  • Lung Cancer
  • Prostate Cancer
  • Bone Cancer

By Region

  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • France
    • UK
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • Japan
    • China
    • Australia
    • India
    • South Korea
    • Rest of Asia-Pacific
  • LAMEA
    • Brazil
    • Saudi Arabia
    • South Africa
    • Rest of LAMEA

Key Market Players:

    • Olympus Corporation
    • AngioDynamics, Inc.
    • Bioventus LLC
    • Johnson & Johnson
    • Medtronic plc
    • ConMed Corporation
    • Smith & Nephew plc
    • Integra LifeSciences Holdings Corporation
    • HealthTronics, Inc.
    • Boston Scientific Corporation

TABLE OF CONTENTS

CHAPTER 1: INTRODUCTION

  • 1.1. Report description
  • 1.2. Key market segments
  • 1.3. Key benefits to the stakeholders
  • 1.4. Research methodology
    • 1.4.1. Primary research
    • 1.4.2. Secondary research
    • 1.4.3. Analyst tools and models

CHAPTER 2: EXECUTIVE SUMMARY

  • 2.1. CXO Perspective

CHAPTER 3: MARKET OVERVIEW

  • 3.1. Market definition and scope
  • 3.2. Key findings
    • 3.2.1. Top impacting factors
    • 3.2.2. Top investment pockets
  • 3.3. Porter's five forces analysis
    • 3.3.1. Low bargaining power of suppliers
    • 3.3.2. Low threat of new entrants
    • 3.3.3. Low threat of substitutes
    • 3.3.4. Low intensity of rivalry
    • 3.3.5. Low bargaining power of buyers
  • 3.4. Market dynamics
    • 3.4.1. Drivers
      • 3.4.1.1. Increase in prevalence of cancers across the globe.
      • 3.4.1.2. Increase in demand for minimally invasive tumor ablation techniques.
    • 3.4.2. Restraints
      • 3.4.2.1. Side-effects associated with tumor ablation treatment.
    • 3.4.3. Opportunities
      • 3.4.3.1. Rise in research and development activities for tumor ablation.

CHAPTER 4: TUMOR ABLATION MARKET, BY TECHNOLOGY

  • 4.1. Overview
    • 4.1.1. Market size and forecast
  • 4.2. Radiofrequency Ablation
    • 4.2.1. Key market trends, growth factors and opportunities
    • 4.2.2. Market size and forecast, by region
    • 4.2.3. Market share analysis by country
  • 4.3. Microwave Ablation
    • 4.3.1. Key market trends, growth factors and opportunities
    • 4.3.2. Market size and forecast, by region
    • 4.3.3. Market share analysis by country
  • 4.4. Cryoablation
    • 4.4.1. Key market trends, growth factors and opportunities
    • 4.4.2. Market size and forecast, by region
    • 4.4.3. Market share analysis by country
  • 4.5. Irreversible Electroporation Ablation
    • 4.5.1. Key market trends, growth factors and opportunities
    • 4.5.2. Market size and forecast, by region
    • 4.5.3. Market share analysis by country
  • 4.6. Other Ablation Technologies
    • 4.6.1. Key market trends, growth factors and opportunities
    • 4.6.2. Market size and forecast, by region
    • 4.6.3. Market share analysis by country

CHAPTER 5: TUMOR ABLATION MARKET, BY TREATMENT

  • 5.1. Overview
    • 5.1.1. Market size and forecast
  • 5.2. Surgical Ablation
    • 5.2.1. Key market trends, growth factors and opportunities
    • 5.2.2. Market size and forecast, by region
    • 5.2.3. Market share analysis by country
  • 5.3. Laparoscopic Ablation
    • 5.3.1. Key market trends, growth factors and opportunities
    • 5.3.2. Market size and forecast, by region
    • 5.3.3. Market share analysis by country
  • 5.4. Percutaneous Ablation
    • 5.4.1. Key market trends, growth factors and opportunities
    • 5.4.2. Market size and forecast, by region
    • 5.4.3. Market share analysis by country

CHAPTER 6: TUMOR ABLATION MARKET, BY APPLICATION

  • 6.1. Overview
    • 6.1.1. Market size and forecast
  • 6.2. Kidney Cancer
    • 6.2.1. Key market trends, growth factors and opportunities
    • 6.2.2. Market size and forecast, by region
    • 6.2.3. Market share analysis by country
  • 6.3. Liver Cancer
    • 6.3.1. Key market trends, growth factors and opportunities
    • 6.3.2. Market size and forecast, by region
    • 6.3.3. Market share analysis by country
  • 6.4. Breast Cancer
    • 6.4.1. Key market trends, growth factors and opportunities
    • 6.4.2. Market size and forecast, by region
    • 6.4.3. Market share analysis by country
  • 6.5. Lung Cancer
    • 6.5.1. Key market trends, growth factors and opportunities
    • 6.5.2. Market size and forecast, by region
    • 6.5.3. Market share analysis by country
  • 6.6. Prostate Cancer
    • 6.6.1. Key market trends, growth factors and opportunities
    • 6.6.2. Market size and forecast, by region
    • 6.6.3. Market share analysis by country
  • 6.7. Bone Cancer
    • 6.7.1. Key market trends, growth factors and opportunities
    • 6.7.2. Market size and forecast, by region
    • 6.7.3. Market share analysis by country

CHAPTER 7: TUMOR ABLATION MARKET, BY REGION

  • 7.1. Overview
    • 7.1.1. Market size and forecast By Region
  • 7.2. North America
    • 7.2.1. Key market trends, growth factors and opportunities
    • 7.2.2. Market size and forecast, by Technology
    • 7.2.3. Market size and forecast, by Treatment
    • 7.2.4. Market size and forecast, by Application
    • 7.2.5. Market size and forecast, by country
      • 7.2.5.1. U.S.
      • 7.2.5.1.1. Market size and forecast, by Technology
      • 7.2.5.1.2. Market size and forecast, by Treatment
      • 7.2.5.1.3. Market size and forecast, by Application
      • 7.2.5.2. Canada
      • 7.2.5.2.1. Market size and forecast, by Technology
      • 7.2.5.2.2. Market size and forecast, by Treatment
      • 7.2.5.2.3. Market size and forecast, by Application
      • 7.2.5.3. Mexico
      • 7.2.5.3.1. Market size and forecast, by Technology
      • 7.2.5.3.2. Market size and forecast, by Treatment
      • 7.2.5.3.3. Market size and forecast, by Application
  • 7.3. Europe
    • 7.3.1. Key market trends, growth factors and opportunities
    • 7.3.2. Market size and forecast, by Technology
    • 7.3.3. Market size and forecast, by Treatment
    • 7.3.4. Market size and forecast, by Application
    • 7.3.5. Market size and forecast, by country
      • 7.3.5.1. Germany
      • 7.3.5.1.1. Market size and forecast, by Technology
      • 7.3.5.1.2. Market size and forecast, by Treatment
      • 7.3.5.1.3. Market size and forecast, by Application
      • 7.3.5.2. France
      • 7.3.5.2.1. Market size and forecast, by Technology
      • 7.3.5.2.2. Market size and forecast, by Treatment
      • 7.3.5.2.3. Market size and forecast, by Application
      • 7.3.5.3. UK
      • 7.3.5.3.1. Market size and forecast, by Technology
      • 7.3.5.3.2. Market size and forecast, by Treatment
      • 7.3.5.3.3. Market size and forecast, by Application
      • 7.3.5.4. Italy
      • 7.3.5.4.1. Market size and forecast, by Technology
      • 7.3.5.4.2. Market size and forecast, by Treatment
      • 7.3.5.4.3. Market size and forecast, by Application
      • 7.3.5.5. Spain
      • 7.3.5.5.1. Market size and forecast, by Technology
      • 7.3.5.5.2. Market size and forecast, by Treatment
      • 7.3.5.5.3. Market size and forecast, by Application
      • 7.3.5.6. Rest of Europe
      • 7.3.5.6.1. Market size and forecast, by Technology
      • 7.3.5.6.2. Market size and forecast, by Treatment
      • 7.3.5.6.3. Market size and forecast, by Application
  • 7.4. Asia-Pacific
    • 7.4.1. Key market trends, growth factors and opportunities
    • 7.4.2. Market size and forecast, by Technology
    • 7.4.3. Market size and forecast, by Treatment
    • 7.4.4. Market size and forecast, by Application
    • 7.4.5. Market size and forecast, by country
      • 7.4.5.1. Japan
      • 7.4.5.1.1. Market size and forecast, by Technology
      • 7.4.5.1.2. Market size and forecast, by Treatment
      • 7.4.5.1.3. Market size and forecast, by Application
      • 7.4.5.2. China
      • 7.4.5.2.1. Market size and forecast, by Technology
      • 7.4.5.2.2. Market size and forecast, by Treatment
      • 7.4.5.2.3. Market size and forecast, by Application
      • 7.4.5.3. Australia
      • 7.4.5.3.1. Market size and forecast, by Technology
      • 7.4.5.3.2. Market size and forecast, by Treatment
      • 7.4.5.3.3. Market size and forecast, by Application
      • 7.4.5.4. India
      • 7.4.5.4.1. Market size and forecast, by Technology
      • 7.4.5.4.2. Market size and forecast, by Treatment
      • 7.4.5.4.3. Market size and forecast, by Application
      • 7.4.5.5. South Korea
      • 7.4.5.5.1. Market size and forecast, by Technology
      • 7.4.5.5.2. Market size and forecast, by Treatment
      • 7.4.5.5.3. Market size and forecast, by Application
      • 7.4.5.6. Rest of Asia-Pacific
      • 7.4.5.6.1. Market size and forecast, by Technology
      • 7.4.5.6.2. Market size and forecast, by Treatment
      • 7.4.5.6.3. Market size and forecast, by Application
  • 7.5. LAMEA
    • 7.5.1. Key market trends, growth factors and opportunities
    • 7.5.2. Market size and forecast, by Technology
    • 7.5.3. Market size and forecast, by Treatment
    • 7.5.4. Market size and forecast, by Application
    • 7.5.5. Market size and forecast, by country
      • 7.5.5.1. Brazil
      • 7.5.5.1.1. Market size and forecast, by Technology
      • 7.5.5.1.2. Market size and forecast, by Treatment
      • 7.5.5.1.3. Market size and forecast, by Application
      • 7.5.5.2. Saudi Arabia
      • 7.5.5.2.1. Market size and forecast, by Technology
      • 7.5.5.2.2. Market size and forecast, by Treatment
      • 7.5.5.2.3. Market size and forecast, by Application
      • 7.5.5.3. South Africa
      • 7.5.5.3.1. Market size and forecast, by Technology
      • 7.5.5.3.2. Market size and forecast, by Treatment
      • 7.5.5.3.3. Market size and forecast, by Application
      • 7.5.5.4. Rest of LAMEA
      • 7.5.5.4.1. Market size and forecast, by Technology
      • 7.5.5.4.2. Market size and forecast, by Treatment
      • 7.5.5.4.3. Market size and forecast, by Application

CHAPTER 8: COMPETITIVE LANDSCAPE

  • 8.1. Introduction
  • 8.2. Top winning strategies
  • 8.3. Product mapping of top 10 player
  • 8.4. Competitive dashboard
  • 8.5. Competitive heatmap
  • 8.6. Top player positioning, 2022

CHAPTER 9: COMPANY PROFILES

  • 9.1. Medtronic plc
    • 9.1.1. Company overview
    • 9.1.2. Key executives
    • 9.1.3. Company snapshot
    • 9.1.4. Operating business segments
    • 9.1.5. Product portfolio
    • 9.1.6. Business performance
  • 9.2. Boston Scientific Corporation
    • 9.2.1. Company overview
    • 9.2.2. Key executives
    • 9.2.3. Company snapshot
    • 9.2.4. Operating business segments
    • 9.2.5. Product portfolio
    • 9.2.6. Business performance
  • 9.3. Smith & Nephew plc
    • 9.3.1. Company overview
    • 9.3.2. Key executives
    • 9.3.3. Company snapshot
    • 9.3.4. Operating business segments
    • 9.3.5. Product portfolio
    • 9.3.6. Business performance
  • 9.4. AngioDynamics, Inc.
    • 9.4.1. Company overview
    • 9.4.2. Key executives
    • 9.4.3. Company snapshot
    • 9.4.4. Operating business segments
    • 9.4.5. Product portfolio
    • 9.4.6. Business performance
    • 9.4.7. Key strategic moves and developments
  • 9.5. HealthTronics, Inc.
    • 9.5.1. Company overview
    • 9.5.2. Key executives
    • 9.5.3. Company snapshot
    • 9.5.4. Operating business segments
    • 9.5.5. Product portfolio
  • 9.6. Bioventus LLC
    • 9.6.1. Company overview
    • 9.6.2. Key executives
    • 9.6.3. Company snapshot
    • 9.6.4. Operating business segments
    • 9.6.5. Product portfolio
    • 9.6.6. Business performance
    • 9.6.7. Key strategic moves and developments
  • 9.7. Johnson & Johnson
    • 9.7.1. Company overview
    • 9.7.2. Key executives
    • 9.7.3. Company snapshot
    • 9.7.4. Operating business segments
    • 9.7.5. Product portfolio
    • 9.7.6. Business performance
    • 9.7.7. Key strategic moves and developments
  • 9.8. ConMed Corporation
    • 9.8.1. Company overview
    • 9.8.2. Key executives
    • 9.8.3. Company snapshot
    • 9.8.4. Operating business segments
    • 9.8.5. Product portfolio
    • 9.8.6. Business performance
  • 9.9. Olympus Corporation
    • 9.9.1. Company overview
    • 9.9.2. Key executives
    • 9.9.3. Company snapshot
    • 9.9.4. Operating business segments
    • 9.9.5. Product portfolio
    • 9.9.6. Business performance
  • 9.10. Integra LifeSciences Holdings Corporation
    • 9.10.1. Company overview
    • 9.10.2. Key executives
    • 9.10.3. Company snapshot
    • 9.10.4. Operating business segments
    • 9.10.5. Product portfolio
    • 9.10.6. Business performance
    • 9.10.7. Key strategic moves and developments

LIST OF TABLES

  • TABLE 01. GLOBAL TUMOR ABLATION MARKET, BY TECHNOLOGY, 2022-2032 ($MILLION)
  • TABLE 02. TUMOR ABLATION MARKET FOR RADIOFREQUENCY ABLATION, BY REGION, 2022-2032 ($MILLION)
  • TABLE 03. TUMOR ABLATION MARKET FOR MICROWAVE ABLATION, BY REGION, 2022-2032 ($MILLION)
  • TABLE 04. TUMOR ABLATION MARKET FOR CRYOABLATION, BY REGION, 2022-2032 ($MILLION)
  • TABLE 05. TUMOR ABLATION MARKET FOR IRREVERSIBLE ELECTROPORATION ABLATION, BY REGION, 2022-2032 ($MILLION)
  • TABLE 06. TUMOR ABLATION MARKET FOR OTHER ABLATION TECHNOLOGIES, BY REGION, 2022-2032 ($MILLION)
  • TABLE 07. GLOBAL TUMOR ABLATION MARKET, BY TREATMENT, 2022-2032 ($MILLION)
  • TABLE 08. TUMOR ABLATION MARKET FOR SURGICAL ABLATION, BY REGION, 2022-2032 ($MILLION)
  • TABLE 09. TUMOR ABLATION MARKET FOR LAPAROSCOPIC ABLATION, BY REGION, 2022-2032 ($MILLION)
  • TABLE 10. TUMOR ABLATION MARKET FOR PERCUTANEOUS ABLATION, BY REGION, 2022-2032 ($MILLION)
  • TABLE 11. GLOBAL TUMOR ABLATION MARKET, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 12. TUMOR ABLATION MARKET FOR KIDNEY CANCER, BY REGION, 2022-2032 ($MILLION)
  • TABLE 13. TUMOR ABLATION MARKET FOR LIVER CANCER, BY REGION, 2022-2032 ($MILLION)
  • TABLE 14. TUMOR ABLATION MARKET FOR BREAST CANCER, BY REGION, 2022-2032 ($MILLION)
  • TABLE 15. TUMOR ABLATION MARKET FOR LUNG CANCER, BY REGION, 2022-2032 ($MILLION)
  • TABLE 16. TUMOR ABLATION MARKET FOR PROSTATE CANCER, BY REGION, 2022-2032 ($MILLION)
  • TABLE 17. TUMOR ABLATION MARKET FOR BONE CANCER, BY REGION, 2022-2032 ($MILLION)
  • TABLE 18. TUMOR ABLATION MARKET, BY REGION, 2022-2032 ($MILLION)
  • TABLE 19. NORTH AMERICA TUMOR ABLATION MARKET, BY TECHNOLOGY, 2022-2032 ($MILLION)
  • TABLE 20. NORTH AMERICA TUMOR ABLATION MARKET, BY TREATMENT, 2022-2032 ($MILLION)
  • TABLE 21. NORTH AMERICA TUMOR ABLATION MARKET, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 22. NORTH AMERICA TUMOR ABLATION MARKET, BY COUNTRY, 2022-2032 ($MILLION)
  • TABLE 23. U.S. TUMOR ABLATION MARKET, BY TECHNOLOGY, 2022-2032 ($MILLION)
  • TABLE 24. U.S. TUMOR ABLATION MARKET, BY TREATMENT, 2022-2032 ($MILLION)
  • TABLE 25. U.S. TUMOR ABLATION MARKET, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 26. CANADA TUMOR ABLATION MARKET, BY TECHNOLOGY, 2022-2032 ($MILLION)
  • TABLE 27. CANADA TUMOR ABLATION MARKET, BY TREATMENT, 2022-2032 ($MILLION)
  • TABLE 28. CANADA TUMOR ABLATION MARKET, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 29. MEXICO TUMOR ABLATION MARKET, BY TECHNOLOGY, 2022-2032 ($MILLION)
  • TABLE 30. MEXICO TUMOR ABLATION MARKET, BY TREATMENT, 2022-2032 ($MILLION)
  • TABLE 31. MEXICO TUMOR ABLATION MARKET, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 32. EUROPE TUMOR ABLATION MARKET, BY TECHNOLOGY, 2022-2032 ($MILLION)
  • TABLE 33. EUROPE TUMOR ABLATION MARKET, BY TREATMENT, 2022-2032 ($MILLION)
  • TABLE 34. EUROPE TUMOR ABLATION MARKET, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 35. EUROPE TUMOR ABLATION MARKET, BY COUNTRY, 2022-2032 ($MILLION)
  • TABLE 36. GERMANY TUMOR ABLATION MARKET, BY TECHNOLOGY, 2022-2032 ($MILLION)
  • TABLE 37. GERMANY TUMOR ABLATION MARKET, BY TREATMENT, 2022-2032 ($MILLION)
  • TABLE 38. GERMANY TUMOR ABLATION MARKET, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 39. FRANCE TUMOR ABLATION MARKET, BY TECHNOLOGY, 2022-2032 ($MILLION)
  • TABLE 40. FRANCE TUMOR ABLATION MARKET, BY TREATMENT, 2022-2032 ($MILLION)
  • TABLE 41. FRANCE TUMOR ABLATION MARKET, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 42. UK TUMOR ABLATION MARKET, BY TECHNOLOGY, 2022-2032 ($MILLION)
  • TABLE 43. UK TUMOR ABLATION MARKET, BY TREATMENT, 2022-2032 ($MILLION)
  • TABLE 44. UK TUMOR ABLATION MARKET, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 45. ITALY TUMOR ABLATION MARKET, BY TECHNOLOGY, 2022-2032 ($MILLION)
  • TABLE 46. ITALY TUMOR ABLATION MARKET, BY TREATMENT, 2022-2032 ($MILLION)
  • TABLE 47. ITALY TUMOR ABLATION MARKET, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 48. SPAIN TUMOR ABLATION MARKET, BY TECHNOLOGY, 2022-2032 ($MILLION)
  • TABLE 49. SPAIN TUMOR ABLATION MARKET, BY TREATMENT, 2022-2032 ($MILLION)
  • TABLE 50. SPAIN TUMOR ABLATION MARKET, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 51. REST OF EUROPE TUMOR ABLATION MARKET, BY TECHNOLOGY, 2022-2032 ($MILLION)
  • TABLE 52. REST OF EUROPE TUMOR ABLATION MARKET, BY TREATMENT, 2022-2032 ($MILLION)
  • TABLE 53. REST OF EUROPE TUMOR ABLATION MARKET, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 54. ASIA-PACIFIC TUMOR ABLATION MARKET, BY TECHNOLOGY, 2022-2032 ($MILLION)
  • TABLE 55. ASIA-PACIFIC TUMOR ABLATION MARKET, BY TREATMENT, 2022-2032 ($MILLION)
  • TABLE 56. ASIA-PACIFIC TUMOR ABLATION MARKET, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 57. ASIA-PACIFIC TUMOR ABLATION MARKET, BY COUNTRY, 2022-2032 ($MILLION)
  • TABLE 58. JAPAN TUMOR ABLATION MARKET, BY TECHNOLOGY, 2022-2032 ($MILLION)
  • TABLE 59. JAPAN TUMOR ABLATION MARKET, BY TREATMENT, 2022-2032 ($MILLION)
  • TABLE 60. JAPAN TUMOR ABLATION MARKET, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 61. CHINA TUMOR ABLATION MARKET, BY TECHNOLOGY, 2022-2032 ($MILLION)
  • TABLE 62. CHINA TUMOR ABLATION MARKET, BY TREATMENT, 2022-2032 ($MILLION)
  • TABLE 63. CHINA TUMOR ABLATION MARKET, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 64. AUSTRALIA TUMOR ABLATION MARKET, BY TECHNOLOGY, 2022-2032 ($MILLION)
  • TABLE 65. AUSTRALIA TUMOR ABLATION MARKET, BY TREATMENT, 2022-2032 ($MILLION)
  • TABLE 66. AUSTRALIA TUMOR ABLATION MARKET, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 67. INDIA TUMOR ABLATION MARKET, BY TECHNOLOGY, 2022-2032 ($MILLION)
  • TABLE 68. INDIA TUMOR ABLATION MARKET, BY TREATMENT, 2022-2032 ($MILLION)
  • TABLE 69. INDIA TUMOR ABLATION MARKET, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 70. SOUTH KOREA TUMOR ABLATION MARKET, BY TECHNOLOGY, 2022-2032 ($MILLION)
  • TABLE 71. SOUTH KOREA TUMOR ABLATION MARKET, BY TREATMENT, 2022-2032 ($MILLION)
  • TABLE 72. SOUTH KOREA TUMOR ABLATION MARKET, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 73. REST OF ASIA-PACIFIC TUMOR ABLATION MARKET, BY TECHNOLOGY, 2022-2032 ($MILLION)
  • TABLE 74. REST OF ASIA-PACIFIC TUMOR ABLATION MARKET, BY TREATMENT, 2022-2032 ($MILLION)
  • TABLE 75. REST OF ASIA-PACIFIC TUMOR ABLATION MARKET, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 76. LAMEA TUMOR ABLATION MARKET, BY TECHNOLOGY, 2022-2032 ($MILLION)
  • TABLE 77. LAMEA TUMOR ABLATION MARKET, BY TREATMENT, 2022-2032 ($MILLION)
  • TABLE 78. LAMEA TUMOR ABLATION MARKET, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 79. LAMEA TUMOR ABLATION MARKET, BY COUNTRY, 2022-2032 ($MILLION)
  • TABLE 80. BRAZIL TUMOR ABLATION MARKET, BY TECHNOLOGY, 2022-2032 ($MILLION)
  • TABLE 81. BRAZIL TUMOR ABLATION MARKET, BY TREATMENT, 2022-2032 ($MILLION)
  • TABLE 82. BRAZIL TUMOR ABLATION MARKET, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 83. SAUDI ARABIA TUMOR ABLATION MARKET, BY TECHNOLOGY, 2022-2032 ($MILLION)
  • TABLE 84. SAUDI ARABIA TUMOR ABLATION MARKET, BY TREATMENT, 2022-2032 ($MILLION)
  • TABLE 85. SAUDI ARABIA TUMOR ABLATION MARKET, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 86. SOUTH AFRICA TUMOR ABLATION MARKET, BY TECHNOLOGY, 2022-2032 ($MILLION)
  • TABLE 87. SOUTH AFRICA TUMOR ABLATION MARKET, BY TREATMENT, 2022-2032 ($MILLION)
  • TABLE 88. SOUTH AFRICA TUMOR ABLATION MARKET, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 89. REST OF LAMEA TUMOR ABLATION MARKET, BY TECHNOLOGY, 2022-2032 ($MILLION)
  • TABLE 90. REST OF LAMEA TUMOR ABLATION MARKET, BY TREATMENT, 2022-2032 ($MILLION)
  • TABLE 91. REST OF LAMEA TUMOR ABLATION MARKET, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 92. MEDTRONIC PLC: KEY EXECUTIVES
  • TABLE 93. MEDTRONIC PLC: COMPANY SNAPSHOT
  • TABLE 94. MEDTRONIC PLC: PRODUCT SEGMENTS
  • TABLE 95. MEDTRONIC PLC: PRODUCT PORTFOLIO
  • TABLE 96. BOSTON SCIENTIFIC CORPORATION: KEY EXECUTIVES
  • TABLE 97. BOSTON SCIENTIFIC CORPORATION: COMPANY SNAPSHOT
  • TABLE 98. BOSTON SCIENTIFIC CORPORATION: PRODUCT SEGMENTS
  • TABLE 99. BOSTON SCIENTIFIC CORPORATION: PRODUCT PORTFOLIO
  • TABLE 100. SMITH & NEPHEW PLC: KEY EXECUTIVES
  • TABLE 101. SMITH & NEPHEW PLC: COMPANY SNAPSHOT
  • TABLE 102. SMITH & NEPHEW PLC: PRODUCT SEGMENTS
  • TABLE 103. SMITH & NEPHEW PLC: PRODUCT PORTFOLIO
  • TABLE 104. ANGIODYNAMICS, INC.: KEY EXECUTIVES
  • TABLE 105. ANGIODYNAMICS, INC.: COMPANY SNAPSHOT
  • TABLE 106. ANGIODYNAMICS, INC.: PRODUCT SEGMENTS
  • TABLE 107. ANGIODYNAMICS, INC.: PRODUCT PORTFOLIO
  • TABLE 108. ANGIODYNAMICS, INC.: KEY STRATERGIES
  • TABLE 109. HEALTHTRONICS, INC.: KEY EXECUTIVES
  • TABLE 110. HEALTHTRONICS, INC.: COMPANY SNAPSHOT
  • TABLE 111. HEALTHTRONICS, INC.: PRODUCT SEGMENTS
  • TABLE 112. HEALTHTRONICS, INC.: PRODUCT PORTFOLIO
  • TABLE 113. BIOVENTUS LLC: KEY EXECUTIVES
  • TABLE 114. BIOVENTUS LLC: COMPANY SNAPSHOT
  • TABLE 115. BIOVENTUS LLC: PRODUCT SEGMENTS
  • TABLE 116. BIOVENTUS LLC: PRODUCT PORTFOLIO
  • TABLE 117. BIOVENTUS LLC: KEY STRATERGIES
  • TABLE 118. JOHNSON & JOHNSON: KEY EXECUTIVES
  • TABLE 119. JOHNSON & JOHNSON: COMPANY SNAPSHOT
  • TABLE 120. JOHNSON & JOHNSON: PRODUCT SEGMENTS
  • TABLE 121. JOHNSON & JOHNSON: PRODUCT PORTFOLIO
  • TABLE 122. JOHNSON & JOHNSON: KEY STRATERGIES
  • TABLE 123. CONMED CORPORATION: KEY EXECUTIVES
  • TABLE 124. CONMED CORPORATION: COMPANY SNAPSHOT
  • TABLE 125. CONMED CORPORATION: PRODUCT SEGMENTS
  • TABLE 126. CONMED CORPORATION: PRODUCT PORTFOLIO
  • TABLE 127. OLYMPUS CORPORATION: KEY EXECUTIVES
  • TABLE 128. OLYMPUS CORPORATION: COMPANY SNAPSHOT
  • TABLE 129. OLYMPUS CORPORATION: PRODUCT SEGMENTS
  • TABLE 130. OLYMPUS CORPORATION: PRODUCT PORTFOLIO
  • TABLE 131. INTEGRA LIFESCIENCES HOLDINGS CORPORATION: KEY EXECUTIVES
  • TABLE 132. INTEGRA LIFESCIENCES HOLDINGS CORPORATION: COMPANY SNAPSHOT
  • TABLE 133. INTEGRA LIFESCIENCES HOLDINGS CORPORATION: PRODUCT SEGMENTS
  • TABLE 134. INTEGRA LIFESCIENCES HOLDINGS CORPORATION: PRODUCT PORTFOLIO
  • TABLE 135. INTEGRA LIFESCIENCES HOLDINGS CORPORATION: KEY STRATERGIES

LIST OF FIGURES

  • FIGURE 01. TUMOR ABLATION MARKET, 2022-2032
  • FIGURE 02. SEGMENTATION OF TUMOR ABLATION MARKET,2022-2032
  • FIGURE 03. TOP IMPACTING FACTORS IN TUMOR ABLATION MARKET (2022 TO 2032)
  • FIGURE 04. TOP INVESTMENT POCKETS IN TUMOR ABLATION MARKET (2022-2032)
  • FIGURE 05. LOW BARGAINING POWER OF SUPPLIERS
  • FIGURE 06. LOW THREAT OF NEW ENTRANTS
  • FIGURE 07. LOW THREAT OF SUBSTITUTES
  • FIGURE 08. LOW INTENSITY OF RIVALRY
  • FIGURE 09. LOW BARGAINING POWER OF BUYERS
  • FIGURE 10. GLOBAL TUMOR ABLATION MARKET:DRIVERS, RESTRAINTS AND OPPORTUNITIES
  • FIGURE 11. TUMOR ABLATION MARKET, BY TECHNOLOGY, 2022 AND 2032(%)
  • FIGURE 12. COMPARATIVE SHARE ANALYSIS OF TUMOR ABLATION MARKET FOR RADIOFREQUENCY ABLATION, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 13. COMPARATIVE SHARE ANALYSIS OF TUMOR ABLATION MARKET FOR MICROWAVE ABLATION, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 14. COMPARATIVE SHARE ANALYSIS OF TUMOR ABLATION MARKET FOR CRYOABLATION, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 15. COMPARATIVE SHARE ANALYSIS OF TUMOR ABLATION MARKET FOR IRREVERSIBLE ELECTROPORATION ABLATION, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 16. COMPARATIVE SHARE ANALYSIS OF TUMOR ABLATION MARKET FOR OTHER ABLATION TECHNOLOGIES, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 17. TUMOR ABLATION MARKET, BY TREATMENT, 2022 AND 2032(%)
  • FIGURE 18. COMPARATIVE SHARE ANALYSIS OF TUMOR ABLATION MARKET FOR SURGICAL ABLATION, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 19. COMPARATIVE SHARE ANALYSIS OF TUMOR ABLATION MARKET FOR LAPAROSCOPIC ABLATION, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 20. COMPARATIVE SHARE ANALYSIS OF TUMOR ABLATION MARKET FOR PERCUTANEOUS ABLATION, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 21. TUMOR ABLATION MARKET, BY APPLICATION, 2022 AND 2032(%)
  • FIGURE 22. COMPARATIVE SHARE ANALYSIS OF TUMOR ABLATION MARKET FOR KIDNEY CANCER, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 23. COMPARATIVE SHARE ANALYSIS OF TUMOR ABLATION MARKET FOR LIVER CANCER, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 24. COMPARATIVE SHARE ANALYSIS OF TUMOR ABLATION MARKET FOR BREAST CANCER, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 25. COMPARATIVE SHARE ANALYSIS OF TUMOR ABLATION MARKET FOR LUNG CANCER, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 26. COMPARATIVE SHARE ANALYSIS OF TUMOR ABLATION MARKET FOR PROSTATE CANCER, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 27. COMPARATIVE SHARE ANALYSIS OF TUMOR ABLATION MARKET FOR BONE CANCER, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 28. TUMOR ABLATION MARKET BY REGION, 2022 AND 2032(%)
  • FIGURE 29. U.S. TUMOR ABLATION MARKET, 2022-2032 ($MILLION)
  • FIGURE 30. CANADA TUMOR ABLATION MARKET, 2022-2032 ($MILLION)
  • FIGURE 31. MEXICO TUMOR ABLATION MARKET, 2022-2032 ($MILLION)
  • FIGURE 32. GERMANY TUMOR ABLATION MARKET, 2022-2032 ($MILLION)
  • FIGURE 33. FRANCE TUMOR ABLATION MARKET, 2022-2032 ($MILLION)
  • FIGURE 34. UK TUMOR ABLATION MARKET, 2022-2032 ($MILLION)
  • FIGURE 35. ITALY TUMOR ABLATION MARKET, 2022-2032 ($MILLION)
  • FIGURE 36. SPAIN TUMOR ABLATION MARKET, 2022-2032 ($MILLION)
  • FIGURE 37. REST OF EUROPE TUMOR ABLATION MARKET, 2022-2032 ($MILLION)
  • FIGURE 38. JAPAN TUMOR ABLATION MARKET, 2022-2032 ($MILLION)
  • FIGURE 39. CHINA TUMOR ABLATION MARKET, 2022-2032 ($MILLION)
  • FIGURE 40. AUSTRALIA TUMOR ABLATION MARKET, 2022-2032 ($MILLION)
  • FIGURE 41. INDIA TUMOR ABLATION MARKET, 2022-2032 ($MILLION)
  • FIGURE 42. SOUTH KOREA TUMOR ABLATION MARKET, 2022-2032 ($MILLION)
  • FIGURE 43. REST OF ASIA-PACIFIC TUMOR ABLATION MARKET, 2022-2032 ($MILLION)
  • FIGURE 44. BRAZIL TUMOR ABLATION MARKET, 2022-2032 ($MILLION)
  • FIGURE 45. SAUDI ARABIA TUMOR ABLATION MARKET, 2022-2032 ($MILLION)
  • FIGURE 46. SOUTH AFRICA TUMOR ABLATION MARKET, 2022-2032 ($MILLION)
  • FIGURE 47. REST OF LAMEA TUMOR ABLATION MARKET, 2022-2032 ($MILLION)
  • FIGURE 48. TOP WINNING STRATEGIES, BY YEAR (2020-2023)
  • FIGURE 49. TOP WINNING STRATEGIES, BY DEVELOPMENT (2020-2023)
  • FIGURE 50. TOP WINNING STRATEGIES, BY COMPANY (2020-2023)
  • FIGURE 51. PRODUCT MAPPING OF TOP 10 PLAYERS
  • FIGURE 52. COMPETITIVE DASHBOARD
  • FIGURE 53. COMPETITIVE HEATMAP: TUMOR ABLATION MARKET
  • FIGURE 54. TOP PLAYER POSITIONING, 2022
  • FIGURE 55. MEDTRONIC PLC: NET SALES, 2021-2023 ($MILLION)
  • FIGURE 56. MEDTRONIC PLC: REVENUE SHARE BY SEGMENT, 2023 (%)
  • FIGURE 57. MEDTRONIC PLC: REVENUE SHARE BY REGION, 2023 (%)
  • FIGURE 58. BOSTON SCIENTIFIC CORPORATION: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 59. BOSTON SCIENTIFIC CORPORATION: REVENUE SHARE BY SEGMENT, 2022 (%)
  • FIGURE 60. BOSTON SCIENTIFIC CORPORATION: REVENUE SHARE BY REGION, 2022 (%)
  • FIGURE 61. SMITH & NEPHEW PLC: NET REVENUE, 2020-2022 ($MILLION)
  • FIGURE 62. SMITH & NEPHEW PLC: REVENUE SHARE BY SEGMENT, 2022 (%)
  • FIGURE 63. SMITH & NEPHEW PLC: REVENUE SHARE BY REGION, 2022 (%)
  • FIGURE 64. ANGIODYNAMICS, INC.: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 65. ANGIODYNAMICS, INC.: REVENUE SHARE BY SEGMENT, 2022 (%)
  • FIGURE 66. ANGIODYNAMICS, INC.: REVENUE SHARE BY REGION, 2022 (%)
  • FIGURE 67. BIOVENTUS LLC: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 68. BIOVENTUS LLC: REVENUE SHARE BY SEGMENT, 2022 (%)
  • FIGURE 69. JOHNSON & JOHNSON: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 70. JOHNSON & JOHNSON: REVENUE SHARE BY SEGMENT, 2022 (%)
  • FIGURE 71. JOHNSON & JOHNSON: REVENUE SHARE BY REGION, 2022 (%)
  • FIGURE 72. CONMED CORPORATION: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 73. CONMED CORPORATION: REVENUE SHARE BY REGION, 2022 (%)
  • FIGURE 74. OLYMPUS CORPORATION: NET REVENUE, 2020-2022 ($MILLION)
  • FIGURE 75. OLYMPUS CORPORATION: REVENUE SHARE BY SEGMENT, 2022 (%)
  • FIGURE 76. INTEGRA LIFESCIENCES HOLDINGS CORPORATION: NET REVENUE, 2020-2022 ($MILLION)
  • FIGURE 77. INTEGRA LIFESCIENCES HOLDINGS CORPORATION: REVENUE SHARE BY SEGMENT, 2022 (%)
  • FIGURE 78. INTEGRA LIFESCIENCES HOLDINGS CORPORATION: REVENUE SHARE BY REGION, 2022 (%)